People channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News
George Scangos, Vir

Vir’s George Scan­gos teams up with his for­mer col­leagues at Bio­gen to press fast-for­ward on an­ti­body pro­grams for coro­n­avirus

Vir CEO George Scangos is in hot pursuit of some antibodies that can combat coronavirus. And he’s turned to one big shop he knows well to cover the manufacturing end of that strategy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot, AstraZeneca (AP Images)

Af­ter a year of big ad­vances, As­traZeneca CEO Pas­cal So­ri­ot takes home a ma­jor-league pay pack­age

By all accounts, 2019 was a great year for AstraZeneca — and it paid off for CEO Pascal Soriot with a big boost in his annual compensation package.

According to the pharma giant’s latest annual report, Soriot bagged a compensation package worth £14.3 million — $18.5 million if you count that in dollars. While his base pay ticked up only slightly, Soriot took home an upsized batch of longterm incentives valued at £10.5 million for 2019 — which compares to total pay valued at £10.4 million in 2017.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Irv Weissman (Norbert von der Groeben for Stanford)

Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

Gilead’s $4.9 billion buyout of Forty Seven, their largest in three years, brought with it a substantial windfall for the biotech’s founder, CEO and earliest investor.

Chief among those winners was Irv Weissman, a well-known stem cell pioneer at Stanford. Weissman and colleague Ravindra Majeti founded the company out of Stanford in 2016, after their early studies showed that some cancer cells use CD47 — healthy cells’ “don’t eat me” signal to the immune system — to evade attack and that you could treat those cancers by blocking the signal.

Markus Enzelberger (Versant)

Ver­sant woos Mor­phoSys' ex-CSO to its boom­ing dis­cov­ery en­gine, with big plans for new star­tups

As MorphoSys celebrated the FDA’s acceptance of its first-ever BLA — complete with a priority review that could lead to a quick OK for its CD19-targeted CAR-T rival — last Monday, former CSO Markus Enzelberger was marking a different milestone of his own.

It was his first day at Versant Ventures’ discovery engine in Basel, a change of scenery after 18 years as the German biotech’s chief scientist. Newly named entrepreneur-in-residence of Ridgeline Therapeutics, Enzelberger expects to spend half of his time evaluating new opportunities for company creation and the other half helping biotech fledglings in the portfolio build the necessary infrastructure.

Nine new coro­n­avirus cas­es are tied to the Bio­gen out­break — as in­fec­tions spread to 'close con­tact­s'

Health officials in Massachusetts have identified 13 new presumptive cases of coronavirus, with 9 of them tied to the Biogen meeting at Boston Marriott Long Wharf. And this time they’re underscoring how staffers are spreading the disease outside the immediate group of 175 meeting attendees.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Macro­Gen­ics los­es CMO Jon Wig­gin­ton as com­mer­cial­iza­tion looms

The next few months are important for MacroGenics. They may soon have their first approved drug. They could even defeat mountainous odds and eclipse Keytruda in a head to head trial.

But whatever they do, they’ll do it without longtime CMO Jon Wigginton.

The cancer biotech announced yesterday that after 7 years, Wigginton will leave the company at the end of the month to pursue a new opportunity. CSO Ezio Bonvini will assume his role while MacroGenics searches for a replacement.

Af­ter a trend­set­ting role in glob­al biotech ven­ture in­vest­ing, David Mott parts ways with NEA

About 12 years ago, David Mott jumped from the CEO suite at MedImmune — after AstraZeneca bought it for $15.6 billion — into one of the busiest roles in biotech venture investing at New Enterprise Associates.

Now he’s hitting the exit, which a spokesperson for NEA says is due to “personal reasons” with plans to spend the bulk of his time wth his family. Mohamad Makhzoumi has been named global head of healthcare investing to replace him in that top spot at NEA.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

Emma Walmsley (GSK via YouTube)

GSK's Em­ma Walm­s­ley award­ed £8.4M pay pack­age af­ter £2.5M rise, fi­nal­ly catch­ing up with fel­low phar­ma CEOs

When Emma Walmsley was first appointed as GlaxoSmithKline’s first woman CEO in 2017, the 25% discrepancy between her salary and that of her predecessor, Andrew Witty, drew a few headlines. After three years at the helm, her salary remains pretty much the same at £1.1 million — but a handsome £5.1 million in performance bonuses has helped trigger a £2.5 million pay rise over the last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.

AM­AG CMO hits the ex­it just as biotech search­es for new CEO to right a ship rocked by Mak­e­na con­tro­ver­sy

Heading into 2020, AMAG Pharmaceuticals has sketched big plans to salvage its wobbly operations — battling a revenue squeeze and a critical FDA review of its preterm birth drug — under a new CEO. Today, it announced that the chief medical officer won’t be staying, either.

Julie Krop, who joined AMAG in 2015, will decamp by the end of the month, leaving a void in the biotech’s development group just as it pledges to persuade the FDA to keep Makena on the market and advance a “potentially exciting pipeline.”

Ver­tex, Seat­tle Ge­net­ics, Alpine with­draw from in­vestor con­fer­ence as biotechs brace for coro­n­avirus

In the first glimpse of how the coronavirus’s growing US spread could disrupt operations at American biotechs, a pair of major companies withdrew today from a large investor conference.

Vertex Pharmaceuticals, Seattle Genetics and Alpine Immune were each scheduled to present Tuesday at the Cowen Healthcare Conference in Boston. All announced on Monday, the first day of the conference, they were canceling their appearances, citing the growing spread of the virus, officially known as SARS-CoV-2.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,000+ biopharma pros reading Endpoints daily — and it's free.